Lactobacillus paracasei LT12 for Uric Acid Reduction and Kidney Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Hyperuricemia, characterized by elevated blood uric acid levels, leads to chronic inflammation and various complications such as gout, diabetes, metabolic syndrome, oxidative stress, hypertension, and kidney injuries, with increasing prevalence due to high purine diets, necessitating effective uric acid reduction and kidney protection methods.

Innovation Solution

The use of Lactobacillus paracasei LT12 and Lactobacillus plantarum CBT LP3, either alone or in combination, to degrade uric acid precursor substances inosine and guanosine, thereby reducing blood uric acid levels and protecting kidney function, with potential applications in preventing or treating associated diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If high purine diet is consumed, then material life level increases, but uric acid levels elevate causing hyperuricemia

Engineering Contradiction:

Improvematerial life levelVSAvoiduric acid levels

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of high purine diet (elevated uric acid) into a beneficial outcome by using probiotics to metabolize purine substances. The probiotics transform the harmful purine accumulation into beneficial metabolic products, thereby reducing uric acid levels while maintaining the ability to consume high purine diets.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces probiotics as an intermediary substance that mediates between the high purine diet and the body's metabolic system. The probiotics act as a bridge, metabolizing purine substances and converting them into less harmful forms, thus protecting against hyperuricemia without restricting dietary choices.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If conventional uric acid reduction methods are used, then uric acid levels decrease, but kidney function may be compromised

Engineering Contradiction:

Improveuric acid levelsVSAvoidkidney function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent employs probiotics that utilize the body's own metabolic pathways to reduce uric acid levels. The probiotics metabolize purine substances through enzymatic actions, allowing the body to self-regulate uric acid levels without external interventions that might harm kidney function.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent changes the metabolic parameters of the body by introducing probiotics that alter purine metabolism. The probiotics modify the biochemical pathways, enhancing the breakdown of purine substances and reducing uric acid production through changes in metabolic activity rather than direct kidney intervention.

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If probiotics are used to reduce uric acid, then blood uric acid levels lower, but degradation of precursor substances must occur

Engineering Contradiction:

Improveblood uric acid levelsVSAvoiddegradation process

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent segments the uric acid reduction process into distinct metabolic steps performed by different probiotic strains. Each strain targets specific precursor substances (inosine, guanosine) and breaks them down through specialized enzymatic actions, dividing the complex degradation process into manageable segments.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent utilizes parameter changes in the microbial metabolism of probiotics to achieve uric acid reduction. The probiotics alter their metabolic parameters (enzyme activity, substrate preference) to efficiently degrade purine precursors, transforming the complex biochemical process into an optimized microbial metabolism system.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The strains significantly lower blood uric acid levels and reduce renal damage, demonstrating efficacy in uric acid reduction and kidney protection, as evidenced by mouse experiments, and can be used in medicaments or food compositions for therapeutic benefits.

Implementation Method 1

Lactobacillus paracasei LT12 and Lactobacillus plantarum CBT LP3 not only have efficacies in degrading uric acid precursor substances inosine and guanosin

Methodology Applied

Scientific EffectEnzyme: Enzyme

Data Source

PatentUS20240165173A1Method of reducing uric acid by using lactobacillus paracasei LT12

Publication Date: 2024.05.23 SHANGHAI LYTONE BIOCHEM

AI summary

The present disclosure provides a method for reducing uric acid by using Lactobacillus paracasei LT12 or Lactobacillus plantarum CBT LP3. The technical schemes provided herein produces the efficacies in reducing uric acid and protecting kidneys, wherein Lactobacillus paracasei LT12 and Lactobacillus plantarum CBT LP3 can effectively degrade inosine and guanosine and reduce production of uric acid, serum creatinine, and blood urea nitrogen; reducing renal pro-inflammatory factor levels; decreasing oxidative damage caused by uric acid production; and promoting uric acid excretion. Mice experiments prove that mice with high uric acid levels, after continuous consumption of the composition of the present invention, have significantly lowered blood uric acid levels. In addition, compared to control group, renal damage is significantly reduced, indicating an improved efficacy in renal protection.